BioMarin Pharmaceutical: reports $283,000,000 IPR&D charge

What happened

• BioMarin Pharmaceutical Inc. filed an 8-K on Oct 6, 2026, reporting that in connection with its acquisition of Alesta Therapeutics B.V., completed on Aug 31, 2026, it expects to record pre-tax charges of approximately $283,000,000 of acquired in-process research and development (IPR&D) expense in its third quarter of 2026 results.
• The filing states the acquisition is expected to result in total pre-tax charges of approximately $320,000,000 for full-year 2026, which include the IPR&D charges and ongoing operating, transaction and transition costs.

Key details

• Acquisition closed: Aug 31, 2026.
• Third quarter 2026 impact: approximately $283,000,000 acquired IPR&D charge; unfavorable impact of about $1.50 to both GAAP diluted EPS and non-GAAP diluted EPS for Q3 2026.
• Full-year 2026 impact: approximately $320,000,000 total pre-tax charges; unfavorable impact of about $1.55 to both GAAP diluted EPS and non-GAAP diluted EPS for full-year 2026.
• BioMarin’s prior full-year 2026 guidance announced on Aug 6, 2026 did not reflect the Alesta acquisition; the company expects to provide updated full-year 2026 guidance with its third quarter 2026 financial results.
• The filing notes results for the quarter ended Sep 30, 2026 have not been finalized and the figures are preliminary and unaudited.

Why it may matter

• This report was filed under Item 2.02 (results of operations and financial condition) and covers preliminary, unaudited estimates of charges and their effects on GAAP and non-GAAP diluted EPS for Q3 2026 and full-year 2026 related to the Alesta acquisition.
• The filing states it does not provide reconciliations for forward-looking non-GAAP measures and warns final results may differ from preliminary estimates. The filing does not show why the company acted.